Bio-Imaging Technologies Announces a Collaborative Working Agreement with the Society of Nuclear Medicine.

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ/NMS: BITI) today announced that it has established a collaborative working agreement with the Society of Nuclear Medicine (SNM), headquartered in Reston, VA. Bio-Imaging and SNM have agreed to work together in establishing multicenter clinical trial capabilities and educational programs.

Mark L. Weinstein, president and chief executive officer of Bio-Imaging, said, "We are very pleased that SNM has chosen to partner with us. We have appreciated the role of nuclear medicine imaging in the drug and medical device development process for some time, and this will allow us to become more involved in an area that is growing and developing rapidly."

Peter S. Conti, M.D., Ph.D., president of SNM, commented, "Over the last few years, the society recognized the need to have nuclear medicine--and in particular PET imaging--used in more clinical trials. We have also recognized the need to help further this technology for drug development." Conti, a professor of radiology, clinical pharmacy and biomedical engineering at the University of Southern California, Los Angeles, added, "As we developed this concept, we looked for an experienced imaging core lab to help support our endeavors and to collaborate in this process. Bio-Imaging has a reputation of operational and scientific experience, and we are pleased to invite them to work with the Society of Nuclear Medicine."

"This important collaboration will help the continued success of nuclear medicine in clinical practice, in drug development and in the emerging molecular imaging field," agreed SNM Vice President-Elect Alexander J. McEwan, M.D., chair of the society's Molecular Imaging and Radionuclide Therapy Trials.

"We are honored to be chosen by SNM to help in the conduct of its clinical trials," stated Colin G. Miller, Ph.D., senior vice president of business development, who went on to say, "We believe the use of nuclear medicine will continue to develop and become more acceptable to the Food and Drug Administration (FDA) for assessing the efficacy and safety of new drugs, biologics and medical devices. Through this collaboration, access to the expertise within the society will also allow us to expand our group of experts and consultants who provides further support to our clients. Furthermore we have identified a number of discrete initiatives on which we are starting to collaborate that will enhance our experience and help develop the use of nuclear medicine in clinical trials. Bio-Imaging education programs are also an area of collaboration with SNM."

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands, and business offices in Massachusetts, the United Kingdom and Germany. Through its CapMed division, Bio-Imaging provides the Personal HealthKey(TM)technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information.

The Society of Nuclear Medicine is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of nuclear medicine and molecular imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances; provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed resource in the field of nuclear and molecular imaging: The Journal of Nuclear Medicine; sponsor research grants, fellowships and awards; and host the premiere nuclear medicine annual meeting. SNM members have developed--and continue to explore--biological and technological innovations in medicine to look noninvasively into the molecular basis of diseases to benefit countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.